핵산 샘플 조제 기기 시장 : 세계 및 지역별 분석 - 제품 유형별, 기술별, 처리 능력별, 최종사용자별, 지역별 - 분석과 예측(2025-2035년)

This report can be delivered within 1 working day.

Introduction of the Nucleic Acid Sample Preparation Instruments Market

The global nucleic acid sample preparation instruments market, initially valued at $910.1 million in 2024, is projected to witness substantial growth, surging to $1,601.8 million by 2035, marking a remarkable compound annual growth rate (CAGR) of 5.10% over the period from 2025 to 2035.

The market is experiencing sustained expansion, driven by the increasing demand for accurate and rapid molecular diagnostics, particularly in the detection of infectious diseases, oncology biomarkers, and genetic disorders. The growing burden of conditions such as cancer, viral infections, and rare genetic diseases has significantly accelerated the need for efficient nucleic acid extraction and purification systems, which form the foundation of downstream applications like PCR and next-generation sequencing (NGS).

A key growth driver is the rising adoption of automated and high-throughput nucleic acid sample preparation instruments, which enhance laboratory efficiency by minimizing manual intervention, reducing human error, and ensuring reproducibility of results. Laboratories are increasingly transitioning toward fully integrated workflows that combine extraction, purification, and analysis, thereby improving turnaround times and enabling large-scale testing, especially in clinical and diagnostic settings. This trend has been further reinforced by the lessons learned during the COVID-19 pandemic, which highlighted the critical importance of scalable and reliable sample preparation technologies.

Moreover, the rapid advancements in genomics and personalized medicine are contributing significantly to market growth. Pharmaceutical and biotechnology companies are investing heavily in research and development activities, where nucleic acid preparation plays a crucial role in biomarker discovery, drug development, and clinical trials. The expanding applications of NGS, liquid biopsy, and gene expression analysis are further boosting demand for advanced preparation instruments capable of handling complex biological samples with high precision.

In addition, increasing government funding and private investments in life sciences research, along with the expansion of academic and research institutes, are supporting market growth globally. Emerging economies are also witnessing rising adoption due to improving healthcare infrastructure and growing awareness of molecular diagnostics. Technological innovations, such as magnetic bead-based extraction, microfluidics, and AI-enabled automation, are enhancing the performance and usability of these instruments, making them more accessible across diverse end users.

Market Introduction

The global nucleic acid sample preparation instruments market has undergone a significant transformation in recent years, evolving from conventional manual extraction techniques to highly automated, high-throughput systems that are integral to modern molecular biology workflows. These instruments play a critical role in the isolation and purification of DNA and RNA from a wide range of biological samples, forming the foundation for downstream applications such as polymerase chain reaction (PCR), next-generation sequencing (NGS), and gene expression analysis.

The market's evolution has been largely driven by the growing demand for precision diagnostics, particularly in areas such as infectious disease detection, oncology, and genetic testing. The increasing shift toward personalized medicine and targeted therapies has further emphasized the need for reliable and efficient nucleic acid preparation technologies. As a result, laboratories across clinical, research, and pharmaceutical settings are increasingly adopting automated solutions that offer improved accuracy, reproducibility, and scalability.

Technological advancements have also played a pivotal role in shaping the market landscape. Innovations such as magnetic bead-based extraction methods, microfluidic platforms, and integrated sample-to-result systems have significantly enhanced workflow efficiency while reducing contamination risks and processing time. Additionally, the integration of automation and digital technologies has enabled seamless handling of large sample volumes, making these instruments indispensable in high-throughput environments.

Furthermore, the expansion of genomics research, coupled with increased funding from governments and private organizations, has accelerated the adoption of advanced nucleic acid sample preparation instruments globally. The experience of large-scale testing during global health crises has reinforced the importance of robust and scalable sample preparation solutions, further driving market growth. Overall, the market continues to advance as a key enabler of innovation in diagnostics, life sciences research, and biopharmaceutical development.

Industrial Impact

The global nucleic acid sample preparation instruments market has witnessed a substantial industrial impact, driven by the increasing integration of advanced sample preparation technologies across diagnostics, life sciences research, and biopharmaceutical manufacturing. As nucleic acid extraction and purification form the backbone of molecular workflows, industries are rapidly adopting automated instruments to enhance operational efficiency, ensure data accuracy, and support large-scale processing requirements. This shift is enabling laboratories and companies to streamline workflows, reduce turnaround times, and minimize manual errors, ultimately improving productivity and cost-effectiveness.

In the pharmaceutical and biotechnology sectors, these instruments have become indispensable for drug discovery, genomic research, and clinical trials. The rising focus on precision medicine and targeted therapies has significantly increased the demand for high-quality nucleic acid samples, directly impacting the adoption of advanced preparation systems. Additionally, the growing use of next-generation sequencing (NGS), liquid biopsy, and biomarker analysis has further strengthened the reliance on automated and high-throughput solutions, creating new growth avenues for instrument manufacturers.

The diagnostics industry has also experienced a notable transformation, as clinical laboratories increasingly incorporate automated nucleic acid preparation systems to manage high testing volumes and maintain consistent results. This has been particularly evident in infectious disease testing and oncology diagnostics, where rapid and reliable sample processing is critical. The industrial shift toward integrated, sample-to-result platforms is further enhancing laboratory capabilities and enabling decentralized testing models.

Moreover, the market is influencing the broader laboratory automation ecosystem, encouraging the development of complementary technologies such as robotic liquid handling systems, microfluidic platforms, and AI-driven data management tools. Manufacturers are focusing on innovation, strategic collaborations, and product differentiation to meet evolving industry needs. As a result, the nucleic acid sample preparation instruments market is not only supporting advancements in healthcare and research but also reshaping industrial practices by promoting automation, scalability, and technological integration across the life sciences value chain.

Market Segmentation:

Segmentation 1: By Product Type

• Nucleic Acid Extraction Systems
• Sample Disruption and Homogenization Instruments
• Liquid Handling and Automation Systems

Nucleic Acid Extraction Systems Segment to Dominate the Nucleic Acid Sample Preparation Instruments Market (by Product Type)

The nucleic acid extraction systems segment is expected to dominate the nucleic acid sample preparation instruments market by product type, owing to its fundamental role in isolating high-quality DNA and RNA required for downstream molecular applications. These systems represent the first and most critical step in workflows such as PCR, next-generation sequencing (NGS), and gene expression analysis, making them indispensable across clinical diagnostics, research laboratories, and pharmaceutical and biotechnology industries.

The dominance of this segment is largely driven by the increasing demand for automated and high-throughput extraction solutions that ensure accuracy, reproducibility, and contamination-free processing. With the rising prevalence of infectious diseases, cancer, and genetic disorders, laboratories are prioritizing reliable extraction systems capable of handling diverse sample types, including blood, tissue, and saliva. Additionally, advancements in technologies such as magnetic bead-based extraction and automated purification platforms have significantly improved efficiency and reduced manual intervention, further boosting adoption.

Moreover, the expansion of molecular diagnostics and genomics research has amplified the need for scalable extraction systems that can support large sample volumes without compromising quality. Pharmaceutical and biotechnology companies are also contributing to segment growth through extensive use of these systems in drug discovery, biomarker identification, and clinical trials. As laboratories continue to transition toward integrated and automated workflows, nucleic acid extraction systems are expected to maintain their leading position, driven by their critical importance in ensuring the reliability and success of downstream analytical processes.

Segmentation 2: By Technology

• Automated Spin-Column based
• Magnetic Bead-Based
• Automated Liquid Handling

Magnetic Bead-Based to Dominate the Nucleic Acid Sample Preparation Instruments Market (by Technology)

Magnetic bead-based technology is expected to dominate the nucleic acid sample preparation instruments market by technology, owing to its superior efficiency, scalability, and compatibility with automated workflows. This method has become the preferred choice for nucleic acid extraction and purification due to its ability to deliver high yield and purity of DNA and RNA across a wide range of sample types, including blood, tissue, and complex biological fluids.

The growing demand for high-throughput and contamination-free processing in molecular diagnostics and genomics research is a key factor driving the adoption of magnetic bead-based systems. Unlike traditional column-based or manual extraction techniques, magnetic bead technology enables seamless automation, reduces hands-on time, and minimizes the risk of cross-contamination, making it highly suitable for clinical laboratories and large-scale testing environments. This is particularly important in applications such as next-generation sequencing (NGS), PCR, and minimal residual disease (MRD) testing, where precision and reproducibility are critical.

Additionally, the flexibility of magnetic bead-based protocols allows for easy integration into robotic liquid handling systems and fully automated platforms, further enhancing laboratory efficiency. Pharmaceutical and biotechnology companies are increasingly utilizing this technology in drug discovery, biomarker research, and clinical trials, contributing to its widespread adoption. Continuous advancements in bead chemistry and automation capabilities are further improving performance and expanding application areas.

As laboratories continue to prioritize speed, accuracy, and scalability, magnetic bead-based technology is expected to maintain its leading position in the market, supported by its strong alignment with the ongoing shift toward automation and advanced molecular workflows.

Segmentation 3: By Throughput

• Low-Throughput Instruments
• Medium-Throughput Instruments
• High-Throughput Instruments

Medium-Throughput Instruments to Dominate the Nucleic Acid Sample Preparation Instruments Market (by Throughput)

Medium-throughput instruments are expected to dominate the nucleic acid sample preparation instruments market by throughput, as they offer an optimal balance among processing capacity, cost-efficiency, and operational flexibility. These systems are particularly well-suited for mid-sized laboratories, diagnostic centers, and research facilities that require consistent sample processing without the high capital investment associated with large-scale, high-throughput platforms.

The dominance of this segment is driven by the growing demand for efficient yet scalable solutions in molecular diagnostics, especially for applications such as infectious disease testing, oncology diagnostics, and genetic analysis. Medium throughput instruments typically support moderate sample volumes, making them ideal for routine laboratory workflows where accuracy, reproducibility, and turnaround time are critical. Their ability to handle varying sample loads without compromising performance makes them a preferred choice across diverse end users.

Additionally, the increasing adoption of automation in laboratories is boosting demand for medium-throughput systems, as they often come equipped with user-friendly interfaces, integrated protocols, and compatibility with advanced extraction technologies such as magnetic bead-based methods. These features help reduce manual intervention, minimize errors, and improve overall laboratory productivity.

Pharmaceutical and biotechnology companies, along with academic and research institutes, are also contributing to the growth of this segment by utilizing medium-throughput instruments for applications such as drug discovery, biomarker research, and clinical trial sample processing. As laboratories continue to seek cost-effective and versatile solutions that adapt to evolving testing needs, medium-throughput instruments are expected to maintain their leading position in the market.

Segmentation 4: By End User

• Academic Research Institutes
• Pharmaceutical and Biotechnology Companies
• Clinical Diagnostic Centers
• Applied Testing (Biobanks, Forensic and Veterinary Laboratories)
• Contract Research Organizations

Academic Research Institutes to Dominate the Nucleic Acid Sample Preparation Instruments Market (by End User)

Academic research institutes are expected to dominate the nucleic acid sample preparation instruments market by end user, driven by their extensive involvement in genomics research, molecular biology studies, and early-stage scientific discovery. These institutions serve as key hubs for innovation, where nucleic acid extraction and purification are fundamental to a wide range of applications, including gene expression analysis, next-generation sequencing (NGS), and functional genomics.

The strong presence of government and private funding for life sciences research has significantly contributed to the growth of this segment. Universities and research centers are increasingly investing in advanced laboratory infrastructure, including automated nucleic acid sample preparation instruments, to enhance research efficiency and ensure high-quality, reproducible results. Additionally, the growing focus on areas such as cancer research, infectious diseases, and genetic disorders has amplified the demand for reliable sample preparation technologies within academic settings.

Academic institutes also play a crucial role in large-scale collaborative projects and consortium-based research, which often require processing high volumes of biological samples. This drives the adoption of both medium- and high-throughput instruments capable of supporting diverse and complex workflows. Furthermore, partnerships between academic institutions and pharmaceutical or biotechnology companies are fostering technology transfer and accelerating the adoption of advanced nucleic acid preparation solutions.

With continuous advancements in genomics and increasing emphasis on precision medicine, academic research institutes are expected to remain a dominant end-user segment, contributing significantly to market growth through sustained research activities, innovation, and demand for cutting-edge laboratory technologies.

Segmentation 5: By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Netherlands
  • Poland
  • Portugal
  • Russia
  • Rest-of-Europe
• Asia-Pacific
  • Australia
  • China
  • India
  • Japan
  • Malaysia
  • South Korea
  • Thailand
  • Taiwan
  • Singapore
  • Indonesia
  • Philippines
  • Rest-of-Asia-Pacific
• Latin America
  • Argentina
  • Brazil
  • Chile
  • Mexico
  • Colombia
  • Rest-of-Latin America
• Middle East and Africa
  • KSA
  • U.A.E.
  • South Africa
  • Rest-of-Middle East and Africa

North America to Dominate the Nucleic Acid Sample Preparation Instruments Market (by Region)

North America is expected to dominate the nucleic acid sample preparation instruments market by region, driven by its well-established healthcare infrastructure, strong presence of leading biotechnology and pharmaceutical companies, and high adoption of advanced molecular diagnostic technologies. The region, particularly the United States, serves as a global hub for genomics research and precision medicine, significantly contributing to the demand for efficient and automated nucleic acid preparation systems.

A key factor supporting regional dominance is the substantial investment in research and development activities by both government bodies and private organizations. Funding from agencies such as the National Institutes of Health (NIH), along with continuous innovation by industry players, has accelerated the adoption of advanced laboratory automation solutions. Additionally, the increasing prevalence of chronic diseases, cancer, and infectious diseases has further boosted the need for reliable molecular testing, thereby driving demand for nucleic acid sample preparation instruments.

North America also benefits from the early adoption of cutting-edge technologies, including next-generation sequencing (NGS), PCR-based diagnostics, and automated liquid handling systems. The presence of major market players and frequent product launches, collaborations, and strategic partnerships further strengthens the region's leadership position. Moreover, the growing focus on personalized medicine and biomarker-based therapies is increasing the reliance on high-quality nucleic acid extraction and purification processes.

Furthermore, the region's robust clinical and research ecosystem, comprising academic institutions, diagnostic laboratories, and biopharmaceutical companies, ensures sustained demand for these instruments. Favorable regulatory frameworks and a strong emphasis on quality and standardization also contribute to widespread adoption. As a result, North America is expected to maintain its dominance in the global nucleic acid sample preparation instruments market over the forecast period.

Recent Developments in the Nucleic Acid Sample Preparation Instruments Market

• In October 2025, AutoGen, Inc. partnered with Sampled to deliver next-generation nucleic acid extraction and multi-omic workflows. Under the agreement, Sampled refers complex extraction projects to AutoGen; AutoGen refers large-scale extraction and downstream analysis to Sampled's integrated laboratory services.
• In April 2025, QIAGEN N.V. announced plans to launch three new sample preparation instruments (QIAsymphony Connect, QIAsprint, QIAmini) in 2025-2026 to improve automation and efficiency across lab segments.

Demand - Drivers, Challenges, and Opportunities

Market Drivers:

Rising Demand for Molecular Diagnostics and Genomic Testing: This market for nucleic acid sample preparation instruments is driven by the shift toward molecular testing. To meet the growing demand for molecular testing, public health and clinical laboratories are giving priority to acquiring automated and repeatable preparation platforms. As testing volumes continue to rise, instrument makers who concentrate on innovation in extraction efficiency, throughput, and integration with downstream workflows are well-positioned to gain a larger portion of the market.

Market Challenges:

High Cost of Instruments: The cost barrier is not merely a pricing issue but a market access challenge that influences purchasing decisions across public and private health systems. To broaden the uptake of nucleic acid sample preparation technologies, instrument manufacturers may need to develop innovative price strategies, modular system alternatives, or finance collaborations, especially for public health laboratories and low and middle-income regions. Latent demand could be unlocked by addressing affordability, the infrastructure for molecular testing could be modernised more quickly, and more equitable access to advanced diagnostics could be supported globally.

Market Opportunities:

Automation and Integrated Workflows: nucleic acid sample preparation instrument manufacturers would need to continue innovation and workflow integration to increase instrument adoption, especially in high-throughput, clinical, and research settings. As demand for molecular diagnostics continues to grow, platforms that deliver seamless, reproducible, and scalable preparation workflows will differentiate themselves by addressing critical laboratory challenges such as turnaround time, quality control, and operational cost efficiency.

How can this report add value to an organization?

Product/Innovation Strategy: The global nucleic acid sample preparation instruments market has been divided into several key segments, including product type, technology, Throughput, end users, and regional markets. By understanding which segments hold the largest share and which ones show potential for growth, this report offers invaluable insights for organizations looking to innovate and expand their product offerings.

Growth/Marketing Strategy: Strategic partnerships, collaborations, and business expansions are anticipated to be central to the growth of the nucleic acid sample preparation instruments market. Key developments and partnerships among diagnostic companies, healthcare providers, and research institutions have already begun to form a significant part of the market dynamics.

Competitive Strategy: The nucleic acid sample preparation instruments Market is highly competitive, with key players such as Thermo Fisher Scientific Inc., QIAGEN N.V., F. Hoffmann-La Roche AG, Danaher Corporation, and Agilent Technologies, Inc. leading through strong product portfolios and continuous innovation. Companies are focusing on automation, advanced extraction technologies, and strategic collaborations to enhance efficiency and expand their market presence, making the landscape dynamic and innovation-driven.

Methodology

Key Considerations and Assumptions in Market Engineering and Validation

• Years from 2024 to 2035 have been considered for the global market size estimation, 2024 has been considered as the base year, and 2025 to 2035 as the forecast period.
• The scope of the report is based on comprehensive inputs from industry experts across various sectors, including specialty clinics and hospitals, diagnostic laboratories, reference laboratories, and research institutions.
• The market contribution of nucleic acid sample preparation instruments is anticipated to grow substantially in the future, with projections based on historical analysis of available solutions.
• Revenues from companies have been sourced from their annual reports for FY2024. For private companies, revenue estimates are derived from primary research inputs, funding history, market collaborations, and operational performance.
• The market has been mapped based on the existing nucleic acid sample preparation instruments, market products, and services. Key companies with significant offerings in this field have been identified and profiled in this report.

Primary Research

The primary sources involve industry experts in the nucleic acid sample preparation instruments market, including the market players offering products and services. Resources such as CEOs, vice presidents, marketing directors, and technology and innovation directors have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

The key data points taken from the primary sources include:

• validation and triangulation of all the numbers and graphs
• validation of report segmentations and key qualitative findings
• understanding the competitive landscape and business model
• current and proposed production values of a product by market players
• validation of the numbers of different segments of the market in focus
• percentage split of individual markets for regional analysis

Secondary Research

Open Sources

• Certified publications, articles from recognized authors, white papers, directories, and major databases, among others
• Annual reports, SEC filings, and investors' presentations of the leading market players
• Company websites and a detailed study of their product portfolio
• Gold standard magazines, journals, white papers, press releases, and news articles
• Paid databases

The key data points taken from the secondary sources include:

• segmentations and percentage shares
• data for market value
• key industry trends of the top players in the market
• qualitative insights into various aspects of the market, key trends, and emerging areas of innovation
• quantitative data for mathematical and statistical calculations

Key Market Players and Competition Synopsis

The companies profiled have been selected based on inputs gathered from an analysis of company coverage, product portfolio, and market penetration.

Some prominent names established in this market are:

• F. Hoffmann-La Roche AG
• Promega Corporation
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
• Tecan Trading AG
• Eppendorf
• Macherey-Nagel GmbH & Co. KG
• Sage Science, Inc.
• Hamilton Company
• Revvity, Inc. (PerkinElmer, Inc.)
• AutoGen Inc.
• Hain Lifescience GmbH / BRUKER
• bioMerieux, Inc.
• Aurora Biomed Inc.
• Genetic Signatures
• Bioteke Corporation

Table of Contents

Executive Summary

Scope and Definition

1 Market: Industry Outlook

• 1.1 Market Overview and Ecosystem
• 1.2 Market Attractiveness: Macro and Micro Factor Analysis
• 1.3 Regulatory Outlook
• 1.4 Pricing Analysis

2 Global Nucleic Acid Sample Preparation Instruments Market Overview

• 2.1 Business Dynamics
  • 2.1.1 Impact Analysis
  • 2.1.2 Market Drivers
    • 2.1.2.1 Rising Demand for Molecular Diagnostics and Genomic Testing
    • 2.1.2.2 High Prevalence of Infectious Diseases and Chronic Conditions
    • 2.1.2.3 Growth in Genomic Research and Personalized Medicine
  • 2.1.3 Market Restraints
    • 2.1.3.1 High Cost of Instruments
    • 2.1.3.2 Technical Complexity and Standardization
  • 2.1.4 Market Opportunities and Trends
    • 2.1.4.1 Opportunities
      • 2.1.4.1.1 Automation and Integrated Workflows
      • 2.1.4.1.2 Growth in Emerging Markets
    • 2.1.4.2 Trends
      • 2.1.4.2.1 Shift toward Magnetic Bead-Based Technology
      • 2.1.4.2.2 Higher Throughput Demand in Clinical Labs

3 Global Nucleic Acid Sample Preparation Instruments Market, 2024-2035, by Product Type

• 3.1 Overview
• 3.2 Growth-Share Matrix
• 3.3 Nucleic Acid Extraction Systems
• 3.4 Sample Disruption and Homogenization Instruments
• 3.5 Liquid Handling and Automation Systems

4 Global Nucleic Acid Sample Preparation Instruments Market, 2024-2035, by Technology

• 4.1 Overview
• 4.2 Growth-Share Matrix
• 4.3 Automated Spin-Column based
• 4.4 Magnetic Bead Based Throughput
• 4.5 Automated Liquid Handling

5 Global Nucleic Acid Sample Preparation Instruments Market, 2024-2035, by Throughput

• 5.1 Overview
• 5.2 Growth-Share Matrix
• 5.3 Low-Throughput Instruments
• 5.4 Medium-Throughput Instruments
• 5.5 High-Throughput Instruments

6 Global Nucleic Acid Sample Preparation Instruments Market, 2024-2035, by End User

• 6.1 Overview
• 6.2 Growth-Share Matrix
• 6.3 Academic Research Institute
• 6.4 Pharmaceutical and Biotechnology Companies
• 6.5 Clinical Diagnostic Centers
• 6.6 Applied Testing (Biobanks, Forensic and Veterinary Laboratories)
• 6.7 Contract Research Organizations

7 Region

• 7.1 Regional Summary
• 7.2 North America
  • 7.2.1 Regional Overview
  • 7.2.2 Driving Factors for Market Growth
  • 7.2.3 Factors Challenging the Market
  • 7.2.4 By Country
    • 7.2.4.1 U.S.
    • 7.2.4.2 Canada
• 7.3 Europe
  • 7.3.1 Regional Overview
  • 7.3.2 Driving Factors for Market Growth
  • 7.3.3 Factors Challenging the Market
  • 7.3.4 By Country
    • 7.3.4.1 Germany
    • 7.3.4.2 U.K.
    • 7.3.4.3 France
    • 7.3.4.4 Italy
    • 7.3.4.5 Spain
    • 7.3.4.6 Netherlands
    • 7.3.4.7 Poland
    • 7.3.4.8 Portugal
    • 7.3.4.9 Russia
    • 7.3.4.10 Rest-of-Europe
• 7.4 Asia Pacific
  • 7.4.1 Regional Overview
  • 7.4.2 Driving Factors for Market Growth
  • 7.4.3 Factors Challenging the Market
  • 7.4.4 By Country
    • 7.4.4.1 Australia
    • 7.4.4.2 China
    • 7.4.4.3 India
    • 7.4.4.4 Japan
    • 7.4.4.5 Malaysia
    • 7.4.4.6 South Korea
    • 7.4.4.7 Thailand
    • 7.4.4.8 Taiwan
    • 7.4.4.9 Singapore
    • 7.4.4.10 Indonesia
    • 7.4.4.11 Philippines
    • 7.4.4.12 Rest-of-Asia-Pacific
• 7.5 Latin America
  • 7.5.1 Regional Overview
  • 7.5.2 Driving Factors for Market Growth
  • 7.5.3 Factors Challenging the Market
  • 7.5.4 By Country
    • 7.5.4.1 Argentina
    • 7.5.4.2 Brazil
    • 7.5.4.3 Chile
    • 7.5.4.4 Mexico
    • 7.5.4.5 Colombia
    • 7.5.4.6 Rest-of-Latin America
• 7.6 Middle East and Africa
  • 7.6.1 Regional Overview
  • 7.6.2 Driving Factors for Market Growth
  • 7.6.3 Factors Challenging the Market
  • 7.6.4 By Country
    • 7.6.4.1 Saudi Arabia
    • 7.6.4.2 South Africa
    • 7.6.4.3 U.A.E.
    • 7.6.4.4 Rest of the Middle East and Africa

8 Markets - Competitive Benchmarking & Company Profiles

• 8.1 Product Benchmarking
• 8.2 Key Strategies and Developments (by Company)
  • 8.2.1 Partnerships, Collaborations, and Business Expansions
  • 8.2.2 New Offerings
• 8.3 Company Share Analysis
• 8.4 Company Profiles
  • 8.4.1 F. Hoffmann-La Roche AG
    • 8.4.1.1 Overview
    • 8.4.1.2 Top Products/Product Portfolio
    • 8.4.1.3 Top Competitors
    • 8.4.1.4 Target Customers
    • 8.4.1.5 Key Personal
    • 8.4.1.6 Analyst View
  • 8.4.2 Promega Corporation
    • 8.4.2.1 Overview
    • 8.4.2.2 Top Products/Product Portfolio
    • 8.4.2.3 Top Competitors
    • 8.4.2.4 Target Customers
    • 8.4.2.5 Key Personal
    • 8.4.2.6 Analyst View
  • 8.4.3 QIAGEN N.V.
    • 8.4.3.1 Overview
    • 8.4.3.2 Top Products/Product Portfolio
    • 8.4.3.3 Top Competitors
    • 8.4.3.4 Target Customers
    • 8.4.3.5 Key Personal
    • 8.4.3.6 Analyst View
  • 8.4.4 Thermo Fisher Scientific Inc.
    • 8.4.4.1 Overview
    • 8.4.4.2 Top Products/Product Portfolio
    • 8.4.4.3 Top Competitors
    • 8.4.4.4 Target Customers
    • 8.4.4.5 Key Personal
    • 8.4.4.6 Analyst View
  • 8.4.5 Tecan Trading AG
    • 8.4.5.1 Overview
    • 8.4.5.2 Top Products/Product Portfolio
    • 8.4.5.3 Top Competitors
    • 8.4.5.4 Target Customers
    • 8.4.5.5 Key Personal
    • 8.4.5.6 Analyst View
  • 8.4.6 Eppendorf
    • 8.4.6.1 Overview
    • 8.4.6.2 Top Products/Product Portfolio
    • 8.4.6.3 Top Competitors
    • 8.4.6.4 Target Customers
    • 8.4.6.5 Key Personal
    • 8.4.6.6 Analyst View
  • 8.4.7 Macherey-Nagel GmbH & Co. KG
    • 8.4.7.1 Overview
    • 8.4.7.2 Top Products/Product Portfolio
    • 8.4.7.3 Top Competitors
    • 8.4.7.4 Target Customers
    • 8.4.7.5 Key Personal
    • 8.4.7.6 Analyst View
  • 8.4.8 Sage Science, Inc.
    • 8.4.8.1 Overview
    • 8.4.8.2 Top Products/Product Portfolio
    • 8.4.8.3 Top Competitors
    • 8.4.8.4 Target Customers
    • 8.4.8.5 Key Personal
    • 8.4.8.6 Analyst View
  • 8.4.9 Hamilton Company
    • 8.4.9.1 Overview
    • 8.4.9.2 Top Products/Product Portfolio
    • 8.4.9.3 Top Competitors
    • 8.4.9.4 Target Customers
    • 8.4.9.5 Key Personal
    • 8.4.9.6 Analyst View
  • 8.4.10 Revvity, Inc. (PerkinElmer, Inc.)
    • 8.4.10.1 Overview
    • 8.4.10.2 Top Products/Product Portfolio
    • 8.4.10.3 Top Competitors
    • 8.4.10.4 Target Customers
    • 8.4.10.5 Key Personal
    • 8.4.10.6 Analyst View
  • 8.4.11 AutoGen Inc.
    • 8.4.11.1 Overview
    • 8.4.11.2 Top Products/Product Portfolio
    • 8.4.11.3 Top Competitors
    • 8.4.11.4 Target Customers
    • 8.4.11.5 Key Personal
    • 8.4.11.6 Analyst View
  • 8.4.12 Hain Lifescience GmbH/BRUKER
    • 8.4.12.1 Overview
    • 8.4.12.2 Top Products/Product Portfolio
    • 8.4.12.3 Top Competitors
    • 8.4.12.4 Target Customers
    • 8.4.12.5 Key Personal
    • 8.4.12.6 Analyst View
  • 8.4.13 bioMerieux, Inc
    • 8.4.13.1 Overview
    • 8.4.13.2 Top Products/Product Portfolio
    • 8.4.13.3 Top Competitors
    • 8.4.13.4 Target Customers
    • 8.4.13.5 Key Personnel
    • 8.4.13.6 Analyst View
  • 8.4.14 Aurora Biomed Inc.
    • 8.4.14.1 Overview
    • 8.4.14.2 Top Products/Product Portfolio
    • 8.4.14.3 Top Competitors
    • 8.4.14.4 Target Customers
    • 8.4.14.5 Key Personnel
    • 8.4.14.6 Analyst View
  • 8.4.15 Genetic Signatures
    • 8.4.15.1 Overview
    • 8.4.15.2 Top Products/Product Portfolio
    • 8.4.15.3 Top Competitors
    • 8.4.15.4 Target Customers
    • 8.4.15.5 Key Personnel
    • 8.4.15.6 Analyst View
  • 8.4.16 Bioteke Corporation
    • 8.4.16.1 Overview
    • 8.4.16.2 Top Products/Product Portfolio
    • 8.4.16.3 Top Competitors
    • 8.4.16.4 Target Customers
    • 8.4.16.5 Key Personnel
    • 8.4.16.6 Analyst View

9 Research Methodology

• 9.1 Data Sources
  • 9.1.1 Primary Data Sources
  • 9.1.2 Secondary Data Sources
  • 9.1.3 Data Triangulation
• 9.2 Market Estimation and Forecast